Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$717.72
+1.6%
$617.37
$510.05
$717.14
$43.83B0.41374,648 shs328,680 shs
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$99.81
-0.8%
$109.51
$81.20
$131.49
$24.00B1.39924,699 shs341,541 shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.77
-0.9%
$24.82
$20.92
$30.43
$140.80B0.5544.96 million shs22.70 million shs
Viatris Inc. stock logo
VTRS
Viatris
$10.53
-0.3%
$9.60
$6.85
$13.55
$12.27B0.9312.57 million shs3.53 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-0.81%-0.24%+4.84%+23.17%+36.55%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
+0.62%-3.98%-6.26%-9.47%+14.06%
Pfizer Inc. stock logo
PFE
Pfizer
+0.80%-0.12%+6.16%+6.47%-14.04%
Viatris Inc. stock logo
VTRS
Viatris
+0.09%+1.44%+19.86%+22.93%-12.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenex SE stock logo
ARGX
argenex
4.0045 of 5 stars
2.53.00.00.03.31.74.4
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.0784 of 5 stars
3.42.00.00.03.50.80.0
Pfizer Inc. stock logo
PFE
Pfizer
4.8129 of 5 stars
2.23.04.24.52.21.73.1
Viatris Inc. stock logo
VTRS
Viatris
1.7948 of 5 stars
0.94.02.50.01.73.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
3.09
Buy$772.847.68% Upside
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.76
Moderate Buy$135.8036.07% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.39
Hold$28.1213.54% Upside
Viatris Inc. stock logo
VTRS
Viatris
1.80
Reduce$10.40-1.19% Downside

Current Analyst Ratings Breakdown

Latest VTRS, PFE, ARGX, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2025
argenex SE stock logo
ARGX
argenex
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$880.00 ➝ $887.00
8/26/2025
argenex SE stock logo
ARGX
argenex
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$818.00
8/26/2025
argenex SE stock logo
ARGX
argenex
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$750.00 ➝ $820.00
8/25/2025
argenex SE stock logo
ARGX
argenex
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$800.00
8/25/2025
argenex SE stock logo
ARGX
argenex
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$850.00
8/14/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$138.00 ➝ $136.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$25.00 ➝ $26.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$32.00 ➝ $33.00
8/6/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$27.00 ➝ $28.00
8/5/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$126.00 ➝ $134.00
8/5/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$170.00 ➝ $150.00
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$3.05B14.39$2.99 per share239.76$99.60 per share7.21
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$2.98B8.06N/AN/A$87.38 per share1.14
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.21$4.37 per share5.67$15.66 per share1.58
Viatris Inc. stock logo
VTRS
Viatris
$14.74B0.83$5.08 per share2.07$13.35 per share0.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$833.04M$19.5036.7366.150.8140.98%21.06%18.25%10/30/2025 (Estimated)
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$719.92M-$1.60N/AN/AN/A-12.20%-1.84%-1.59%11/3/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8813.178.170.8816.84%21.42%9.12%11/4/2025 (Estimated)
Viatris Inc. stock logo
VTRS
Viatris
-$634.20M-$2.90N/A4.10N/A-24.57%16.54%7.06%11/6/2025 (Estimated)

Latest VTRS, PFE, ARGX, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Viatris Inc. stock logo
VTRS
Viatris
$0.56$0.62+$0.06N/A$3.46 billion$3.58 billion
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
8/4/2025Q2 2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.41-$1.60-$0.19-$1.82$161.26 million$306.46 million
7/31/2025Q2 2025
argenex SE stock logo
ARGX
argenex
$2.84$3.74+$0.90$3.74$776.82 million$866.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.95%N/A91.49%16 Years
Viatris Inc. stock logo
VTRS
Viatris
$0.484.56%N/AN/A N/A

Latest VTRS, PFE, ARGX, and BNTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2025
Viatris Inc. stock logo
VTRS
Viatris
quarterly$0.125.37%8/22/20258/22/20259/15/2025
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.60
5.27
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.61
8.48
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85
Viatris Inc. stock logo
VTRS
Viatris
0.94
1.37
0.77

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Viatris Inc. stock logo
VTRS
Viatris
79.88%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Viatris Inc. stock logo
VTRS
Viatris
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,59961.20 million59.71 millionOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
6,772240.40 million194.24 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Viatris Inc. stock logo
VTRS
Viatris
32,0001.17 billion1.16 billionOptionable

Recent News About These Companies

Insider Watch: 3 CEOs Buying the Dip
3 Stocks Under $50 Walking a Fine Line
3 Hyped Up Stocks That Fall Short
Viatris (VTRS) Gets a Sell from Bank of America Securities
Viatris first to win US approval for generic Venofer
Viatris Earnings Call: Growth Amid Challenges
Why Viatris (VTRS) Stock Is Up Today
Viatris Expands Board with New Appointment

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenex stock logo

argenex NASDAQ:ARGX

$717.72 +11.31 (+1.60%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$99.80 -0.82 (-0.81%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Pfizer stock logo

Pfizer NYSE:PFE

$24.76 -0.22 (-0.86%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Viatris stock logo

Viatris NASDAQ:VTRS

$10.52 -0.04 (-0.33%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.